Effects of Depression and Serotonergic Antidepressants on Bone: Mechanisms and Implications for the Treatment of Depression

被引:60
作者
Fernandes, Brisa S. [1 ,2 ]
Hodge, Jason M. [3 ,4 ]
Pasco, Julie A. [1 ,5 ]
Berk, Michael [1 ,6 ]
Williams, Lana J. [1 ]
机构
[1] Deakin Univ, Sch Med, IMPACT Strateg Res Ctr, POB 281, Geelong, Vic 3220, Australia
[2] Univ Fed Rio Grande do Sul, Dept Biochem, Lab Calcium Binding Prot Cent Nervous Syst, Porto Alegre, RS, Brazil
[3] Barwon Hlth Univ Hosp, Barwon Biomed Res, Geelong, Vic, Australia
[4] Deakin Univ, Sch Med, MMR Strateg Res Ctr, Geelong, Vic 3217, Australia
[5] Univ Melbourne, Dept Med, St Albans, Vic, Australia
[6] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Dept Psychiat & Orygen, Natl Ctr Excellence Youth Mental Hlth, Parkville, Vic 3052, Australia
基金
英国医学研究理事会;
关键词
TRANSPORTER INHIBITION EVIDENCE; REUPTAKE INHIBITORS; PSYCHIATRIC-DISORDERS; MINERAL DENSITY; RISK; MASS; EPIDEMIOLOGY; OSTEOPOROSIS; METAANALYSIS; ASSOCIATION;
D O I
10.1007/s40266-015-0323-4
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
030301 [社会学]; 100201 [内科学];
摘要
Osteoporosis is a chronic skeletal disease marked by microarchitectural deterioration of the bone matrix and depletion of bone mineral density (BMD), with a consequent increased risk for fragility fractures. It has been frequently associated with depression, which is also a chronic and debilitating disorder with high prevalence. Selective serotonin reuptake inhibitors (SSRIs), first-line agents in the pharmacological treatment of mood and anxiety disorders, have also been shown to negatively affect bone metabolism. SSRIs are the most prescribed antidepressants worldwide and a large number of persons at risk of developing osteoporosis, including older patients, will receive these antidepressants. Therefore, a proper musculoskeletal evaluation of individuals who are being targeted for or using SSRIs is a priority. The aim of this article is to review the evidence regarding the effects of depression and serotonergic antidepressants on bone and its implications for clinical care.
引用
收藏
页码:21 / 25
页数:5
相关论文
共 47 条
[1]
The "depressive" face of osteoporosis and the "osteoporotic" face of depression [J].
Aloumanis, Kyriakos ;
Mavroudis, Kostantinos .
HORMONES-INTERNATIONAL JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2013, 12 (03) :350-362
[2]
Depression, selective serotonin reuptake inhibitors and osteoporosis [J].
Bab I. ;
Yirmiya R. .
Current Osteoporosis Reports, 2010, 8 (4) :185-191
[3]
Update in Serotonin and Bone [J].
Bliziotes, Michael .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (09) :4124-4132
[4]
Neurotransmitter action in osteoblasts: Expression of a functional system for serotonin receptor activation and reuptake [J].
Bliziotes, MM ;
Eshleman, AJ ;
Zhang, XW ;
Wiren, KM .
BONE, 2001, 29 (05) :477-486
[5]
Adult Tph2 knockout mice without brain serotonin have moderately elevated spine trabecular bone but moderately low cortical bone thickness [J].
Brommage, Robert ;
Liu, Jeff ;
Doree, Deon ;
Yu, Wangsheng ;
Powell, David R. ;
Yang, Qi Melissa .
BONEKEY REPORTS, 2015, 4
[6]
Carter MJ, 2014, THER RECREAT J, V48, P275
[7]
Decreased osteoclastogenesis in serotonin-deficient mice [J].
Chabbi-Achengli, Yasmine ;
Coudert, Amelie E. ;
Callebert, Jacques ;
Geoffroy, Valerie ;
Cote, Francine ;
Collet, Corinne ;
de Vernejoul, Marie-Christine .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (07) :2567-2572
[8]
Do SSRIs Play a Role in Decreasing Bone Mineral Density? [J].
Chen, Fonda ;
Hahn, Theodore J. ;
Weintraub, Nancy T. .
JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION, 2012, 13 (05) :413-417
[9]
CHRISTIANSEN C, 1991, AM J MED, V90, P107
[10]
The serotonin 5-HT2B receptor controls bone mass via osteoblast recruitment and proliferation [J].
Collet, C. ;
Schiltz, C. ;
Geoffroy, V. ;
Maroteaux, L. ;
Launay, J. -M. ;
de Vernejoul, M. -C. .
FASEB JOURNAL, 2008, 22 (02) :418-427